Clinical Trials Logo

ADHD - Combined Type clinical trials

View clinical trials related to ADHD - Combined Type.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06465641 Not yet recruiting - Clinical trials for ADHD - Combined Type

Methylphenidate in KBG Syndrome: N-of-1 Series

KBGS_N_of_1
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is: • What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome? Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.

NCT ID: NCT06235177 Not yet recruiting - Anxiety Clinical Trials

Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues

PNMD
Start date: July 24, 2024
Phase: Early Phase 1
Study type: Interventional

Psychoneuromentalism Disorder is a disorder arising in the mind; that is related to the mental and emotional state of a person. It is the science of mental life. The body has a natural design to heal itself. This is a mental phenomena that cannot be explained, until now. Psychoneuromentalism Disorder is a new condition resulting from behavioral impairments, neurodiversity, and neurobehavioral dysfunctions that are related to the mental and emotional state of a participant.

NCT ID: NCT06081348 Not yet recruiting - Anxiety Clinical Trials

Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

CALM
Start date: October 2023
Phase: Phase 2
Study type: Interventional

There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.